Lantheus to Present at the Jefferies London Healthcare Conference
BEDFORD, Mass. — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a leader in the field of radiopharmaceuticals, is excited to announce that Bob Marshall, the Chief Financial Officer and Treasurer, will be representing the company at the upcoming Jefferies London Healthcare Conference. His presentation is scheduled for 1:00 p.m. GMT (8 a.m. EST) on a Wednesday in late November.
What to Expect from the Presentation
During this presentation, Lantheus will focus on its innovative radiopharmaceutical solutions that are designed to enable clinicians to effectively Find, Fight, and Follow diseases. This mission is at the heart of Lantheus’s commitment to improving patient outcomes and transforming healthcare practices.
Understanding Radiopharmaceuticals
Radiopharmaceuticals integrate radioactive substances with pharmaceutical compounds to target specific diseases or conditions within the body. Lantheus has been pioneering this approach for over 65 years, providing critical tools that enhance the diagnostic and therapeutic capabilities in medicine.
Company Commitment to Healthcare
Lantheus plays a vital role in the healthcare ecosystem by offering products that help in the early detection and management of serious diseases. The company's investments in research and development have allowed it to remain at the forefront of the industry.
Live Webcast Access and Replay Availability
To engage with Lantheus during the Jefferies Healthcare Conference, interested parties can access the live webcast via the Investors section of the company’s official website. Furthermore, a replay of the presentation will be accessible on the site for a minimum of 30 days post-event. This flexibility ensures that a broader audience can benefit from the insights shared during the conference.
About Lantheus Holdings, Inc.
Lantheus has solidified its position as a foremost radiopharmaceutical-focused company, delivering groundbreaking science to improve the healthcare journey. With headquarters located in Massachusetts and additional offices in Canada and Sweden, Lantheus's global presence enhances its ability to serve communities effectively. Their commitment to delivering state-of-the-art radiopharmaceutical solutions underscores their long-standing dedication to fostering better patient outcomes.
Reach Out to Lantheus
For those wishing to learn more about Lantheus's innovations or to inquire about their radiopharmaceutical offerings, the company’s representatives are readily available. Mark Kinarney, Vice President of Investor Relations, can be reached at 978-671-8842. Additionally, for communication related to media inquiries, Melissa Downs, Senior Director of External Communications, is on hand at 646-975-2533.
Frequently Asked Questions
What is the main focus of Lantheus at the conference?
Lantheus will showcase its advancements in radiopharmaceuticals aimed at improving disease detection and management.
Who will represent Lantheus at the conference?
Bob Marshall, the Chief Financial Officer and Treasurer of Lantheus, will present at the conference.
How can I access the live presentation?
The live presentation can be accessed through the Investors section of Lantheus's official website.
Will the presentation be available after the event?
Yes, there will be a replay available on the Lantheus website for at least 30 days following the live presentation.
What is the mission statement of Lantheus?
Lantheus aims to enable clinicians to Find, Fight, and Follow disease, ultimately leading to better patient outcomes.
